Like Saxenda (liraglutide), Ozempic (semaglutide) and WeGovy (semaglutide) have been shown to be effective in reducing HbA1c levels and promoting weight loss in people with type 2 diabetes
TRICARE Prime and Select users retain coverage for these medications under these conditions, while all beneficiaries are still covered for GLP-1 medications to treat Type 2 diabetes
No significant changes in BTMs were observed in either group
Its also worth noting that there are many time-tested therapiesmedications that have been on the market for 10 to 60+ yearsthat can still be perfectly viable solutions when matched with a patients current health status and needs
In summary, the mechanistic picture suggests GLP-1 RAs could improve the fertile milieu by aiding weight loss and reducing metabolic inhibitors of fertility, and they may even directly improve certain sperm functions, but they are not magic bullets for restoring testosterone in severely obese or diabetic states (at least in isolation)
It added, however, that the manufacturing authorisation holders (MAHs) for GLP-1 agonists will continue to monitor these events closely. Last year, the PRAC also concluded there was no increased risk of thyroid cancer with Ozempic and Trulicity in a separate review.